ReviewThe American journal of gastroenterology2016
Biomarkers in Search of Precision Medicine in IBD.
Review in The American journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Vedolizumab for induction and maintenance of remission in Crohn's disease.The Cochrane database of systematic reviews · 2023Pooled it
- Spatial multi-omics-guided drug development in inflammatory bowel disease: from mucosal immune niches to precision therapy.Frontiers in immunology · 2026Review
- Stabilized and unstabilized sampling methods result in differential fecal 16S rRNA microbial sequencing results.PloS one · 2025Article
- Computer-Aided Imaging Analysis of Probe-Based Confocal Laser Endomicroscopy With Molecular Labeling and Gene Expression Identifies Markers of Response to Biological Therapy in IBD Patients: The Endo-Omics Study.Inflammatory bowel diseases · 2023Article
- Harnessing the Power of Precision Medicine and Novel Biomarkers to Treat Crohn's Disease.Journal of clinical medicine · 2023Review
- Article
- Central resources of variant discovery and annotation and its role in precision medicine.Asian biomedicine : research, reviews and news · 2022Review
- Article
- Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease.Journal of personalized medicine · 2021Article
- Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.Journal of Crohn's & colitis · 2021Review
- Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.Journal of Crohn's & colitis · 2021Article
- Inflammatory Bowel Disease Through the Lens of Single-cell RNA-seq Technologies.Inflammatory bowel diseases · 2020Review
- Ulcerative colitis.Nature reviews. Disease primers · 2020Review
- Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults.Diagnostics (Basel, Switzerland) · 2020Review
- Comparative Analyses of the Conformational Dynamics Between the Soluble and Membrane-Bound Cytokine Receptors.Scientific reports · 2020Article
- ILC2 Proliferated by IL-33 Stimulation Alleviates Acute Colitis in Rag1Journal of immunology research · 2020Article
- Article
- Big data in IBD: a look into the future.Nature reviews. Gastroenterology & hepatology · 2019Review
- Recent Advances in the Etiopathogenesis of Inflammatory Bowel Disease: The Role of Omics.Molecular diagnosis & therapy · 2018Review
- Diagnostic Potential of Systemic Eosinophil-Associated Cytokines and Growth Factors in IBD.Gastroenterology research and practice · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
The completion of the human genome project in 2003 represented a major scientific landmark, ushering in a new era with hopes and expectations of fresh insights into disease mechanisms and treatments. In inflammatory bowel disease (IBD), many important discoveries soon followed, notably the identification of >200 genetic susceptibility loci and characterization of the gut microbiome. As "big data", driven by advances in technology, becomes increasingly available and affordable, individuals with IBD and clinicians alike yearn for tangible outcomes from the promise of "precision medicine"-precise diagnosis, monitoring, and treatment. Here, we provide a commentary on the prospects and challenges of precision medicine and biomarkers in IBD. We focus on the three key areas where precision IBD will have the most impact: (1) disease susceptibility, activity, and behavior; (2) prediction of drug response and adverse effects; and (3) identification of subphenotypic mechanisms to facilitate drug discovery and selection of new treatments in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.